| 000 | 01147 a2200301 4500 | ||
|---|---|---|---|
| 005 | 20250514070905.0 | ||
| 264 | 0 | _c20060323 | |
| 008 | 200603s 0 0 eng d | ||
| 022 | _a1744-7631 | ||
| 024 | 7 |
_a10.1517/14728222.7.3.385 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aFingleton, Barbara | |
| 245 | 0 | 0 |
_aMatrix metalloproteinase inhibitors for cancer therapy:the current situation and future prospects. _h[electronic resource] |
| 260 |
_bExpert opinion on therapeutic targets _cJun 2003 |
||
| 300 |
_a385-97 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aAntineoplastic Agents _xpharmacology |
| 650 | 0 | 4 | _aClinical Trials as Topic |
| 650 | 0 | 4 | _aForecasting |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMatrix Metalloproteinase Inhibitors |
| 650 | 0 | 4 |
_aMatrix Metalloproteinases _xphysiology |
| 650 | 0 | 4 |
_aNeoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aProtease Inhibitors _xpharmacology |
| 650 | 0 | 4 | _aTreatment Outcome |
| 773 | 0 |
_tExpert opinion on therapeutic targets _gvol. 7 _gno. 3 _gp. 385-97 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1517/14728222.7.3.385 _zAvailable from publisher's website |
| 999 |
_c12569140 _d12569140 |
||